At least 18 years old at the time of signing the main study informed consent form (ICF).
Histologically confirmed:
Dose Escalation (all cohorts): Grades 1-3 WD, metastatic or locally advanced and unresectable NET at any primary site, including, but not limited to, GI, pancreatic, lung, thyroid, breast, urogenital, and adrenal tumors.
Dose Expansion Cohort A: Grades 1-3 WD, metastatic or locally advanced and unresectable GEP-NETs
Dose Expansion Cohort B: metastatic or locally advanced and unresectable tumors known to frequently express SSTR, limited to the following indications:
* WD NETs (Grades 1-3) from primary sites other than gastrointestinal and pancreatic (including, but not limited to, lung, thyroid, breast, urogenital, and adrenal tumors) Meningioma (Grades 1-3)
* SSTR-positive disease, as assessed by SSTR-PET imaging
* Adequate renal, hematologic and hepatic function
You may not be if
Prior RPT, including Lu-177.
Prior solid organ or bone marrow transplantation.
Use of chronic systemic steroid therapy.
Significant cardiovascular disease
Resistant hypertension
Uncontrolled diabetes
Prior history of liver cirrhosis
HIV, hepatitis B infection or known active hepatitis C virus infection.
Note: Additional criteria may apply and will be assessed by the study site
Clareo Health | Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
